Journal
CURRENT RHEUMATOLOGY REPORTS
Volume 20, Issue 2, Pages -Publisher
SPRINGER
DOI: 10.1007/s11926-018-0709-5
Keywords
Systemic sclerosis; Pulmonary hypertension; SSc; PAH; Scleroderma; Connective tissue disease
Categories
Funding
- United Therapeutics
- Third Rock Venture
- Reata
- Gilead
- Actelion
Ask authors/readers for more resources
Purpose of Review This review will summarize the most current literature on the clinical impact, epidemiology, risk factors, screening recommendations, predictors of outcomes, and treatment options in patients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc). Recent Findings PAH continues to be a major cause of morbidity and mortality in SSc. Many risk factors and predictors of outcomes have been identified in patients with SSc including clinical, hemodynamic, and laboratory parameters. Screening for PAH in SSc patients is important and screening algorithms have been developed. Despite many available treatment options for PAH, prognosis remains poor. Summary Awareness of risk factors, early detection, and up-front combination treatment are important considerations in SSc-PAH and may lead to improved outcomes. Further research to develop better biomarkers and therapies is needed to continue to improve survival and outcomes in patients with SSc-PAH.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available